Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, 2 days ago
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.

Changes in NT-proBNP tied to higher cardiovascular risk in NSTEACS

25 Jul 2017

Changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) are associated with cardiovascular risks in non-ST-segment elevation acute coronary syndrome (NSTEACS), a new study has shown.

In 1,665 NSTEACS patients (median age 65.0 years; 38.3 percent female), the change in NT-proBNP levels from baseline to six months was significantly associated with higher risks of CV death (hazard ratio [HR], 1.14; 95 percent CI, 1.03 to 1.27; p=0.01) and all-cause death (HR, 1.14; 1.04 to 1.26; p<0.01).

In comparison, only the risk of all-cause death was significantly associated with the change in NT-proBNP from baseline to 30 days (HR, 1.15; 1.03 to 1.28; p=0.01).

NT-proBNP levels at baseline and at 30 days were associated significantly with cardiovascular (CV) death (HR, 1.17; 1.07 to 1.28; p<0.01 and HR, 1.24; 1.09 to 1.41; p<0.01, respectively), all-cause death (HR, 1.15; 1.06 to 1.25; p<0.01 and HR, 1.23; 1.09 to 1.38; p<0.01, respectively) and CV events (HR, 1.07; 1.01 to 1.14; p=0.02 and HR, 1.11; 1.02 to 1.22; p=0.02, respectively).

Additionally, NT-proBNP levels at 6 months were also significantly associated with CV events (HR, 1.13; 1.04 to 1.24; p<0.01), CV death (HR, 1.20; 1.08 to 1.33; p<0.01), myocardial infarction (MI; HR, 1.15; 1.02 to 1.30; p=0.02) and all-cause death (HR, 1.18; 1.07 to 1.29; p<0.01).

On the other hand, only the change in hs-CRP from baseline to 6 months was associated with higher risks of CV events (HR, 1.09; 1.02 to 1.17; p=0.02) and myocardial infarction (HR, 1.10; 1.00 to 1.20; p=0.04).

NT-proBNP and hs-CRP levels were measured at three timepoints: at baseline, at 30 days and at 6 months. The primary endpoint was the composite outcome of CV death, nonfatal stroke and nonfatal MI. Cox proportional hazards was used to determine the correlation of biomarker levels with cardiovascular outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, 2 days ago
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.